ClinicalTrials.gg
RecruitingNCT05801224Updated Oct 2, 2026

Vascular ARDS Recruitment After Inhaled Nitric Oxide

An interventional study of Nitric Oxide in Acute Respiratory Distress Syndrome and Ventilation Perfusion Mismatch, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 2, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Respiratory Distress Syndrome by Massachusetts General Hospital — 1 open to participants now, 2 under way, none of them phase 3. Respiratory Distress Syndrome · Massachusetts General Hospital.

Started
2026
the only one that year
No phase
4 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Respiratory Distress Syndrome by Massachusetts General Hospital, this one is the only one that started in 2026, is one of 4 with no phase, and was the 10th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

1 of the 11 studies in Respiratory Distress Syndrome by Massachusetts General Hospital is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Respiratory Distress Syndrome by Massachusetts General Hospital, or all of them as a file.
02

Study summary

Acute respiratory distress syndrome (ARDS) is when a person's lungs become inflamed, which can be caused by infection, trauma, surgery, blood transfusion, or burn. ARDS often leads to a situation where the person cannot breathe independently and needs machines' help. Once the lungs are inflamed, the small air sacs responsible for exchanging gases (i.e., ventilation) and the blood flow in the lungs (i.e., perfusion) can be affected. In the past, most research focused on studying ventilation physiology and how to help people breathe with machines. Less was done on perfusion because it requires imaging techniques such as computed tomography with intravenous contrast and radiation. One treatment option for low oxygen levels is inhaled nitric oxide (iNO), a gas that can dilate the lung blood vessels and improve oxygenation; however, it is not always clear whether this treatment will work.

Prone position has been used for several years in the care of ARDS patients and has been demonstrated to improve survival in more severe patients. It is not known how iNO and prone positioning interact in determining the distribution of pulmonary perfusion and whether their combine use can benefit ARDS patients.

Electrical Impedance Tomography (EIT) is a bedside and accessible imaging technique that is radiation-free and non-invasive and can potentially detect changes in lung perfusion. EIT can perform multiple measurements; it is portable and accessible. This prospective interventional study aims to assess changes in regional blood perfusion in the lungs of patients with ARDS in response to iNO and to prone positioning utilizing EIT. The main questions it aims to answer are:

  1. If EIT can measure lung regional perfusion response to an iNO challenge of 20ppm for 15 minutes.
  2. If EIT can measure the lung regional perfusion responses to prone position, applied alone and in combination with iNO.
  3. If EIT is comparable to dual-energy computed tomography (DECT), the gold-standard method, in the detection of changes in regional lung perfusion due to iNO.
  4. If EIT can be an imaging marker to identify ARDS severity

Participants will be divided into three cohorts:

  1. Sub-Cohort 1 (n=60): Participants will be asked to be monitored by EIT before, during, and after the administration of iNO (20 ppm) for 15 minutes (OFF-ON-OFF) in the supine position
  2. Sub-Cohort 2 (N=10): Participants will be asked to be monitored by EIT before and during the administration of iNO (20 ppm) for 15 minutes (OFF-ON) in both the supine and in the prone position. The same subjects will be monitored also with DECT in the supine position and then after 30 minutes in the prone position (without NO administration).
  3. Sub-Cohort 3 (N=10): In this subset of Sub-Cohort 1, subjects will be asked to be monitored also with DECT (in addition to EIT) in the supine body position before iNO and after 15 minutes while receiving iNO.
Read the detailed description

The investigators will screen patients with ARDS diagnosis daily at MGH intensive care units and work in the consenting process with the ICU team and surrogates. The enrollment period will be limited to the time subjects will undergo the study procedures. Subjects will exit the study as soon as the study procedures are completed. No further procedures are planned; therefore, subjects will not be asked to return to the hospital exclusively for research-related purposes.

The enrolled subjects (n=70) will be divided into three sub-cohorts. Sub-Cohort 1 (n=60) will be monitored with EIT before, during, and after the administration of iNO (OFF-ON-OFF). Sub-Cohort 2 (n=10) will be monitored with EIT before and during the administration of iNO (OFF-ON) in the supine and in the prone position, and with DECT in the supine and in the prone position (without iNO). Sub-Cohort 3 (n=10) will be a subset of Cohort 1 and will be monitored with DECT before and during the administration of iNO, in addition to EIT monitoring before, during and after iNO administration (OFF-ON-OFF).

Methods to answer question 1 (To measure the topographic perfusion response to an iNO challenge with EIT):

- The EIT monitoring will be composed of ventilation and perfusion distributions. First, the ventilation is recorded; at this point, no additional maneuver is needed; the subjects need to wear the electrode belt connected to the device, and their ventilation will be recorded. Secondly, for the perfusion distribution, after a pause in the ventilation, EIT measures the distribution of blood perfusion in the lungs during the injection of a 10 mL bolus of 11.7% hypertonic saline solution through a central venous catheter. Cohort 1 (n=60) will receive 20ppm of iNO for 15 minutes. Cohort 1 will be monitored with EIT before, during, and after the iNO delivery in an OFF-ON-OFF fashion.

Methods to answer question 2 (To measure the topographic perfusion response to prone position, applied alone and in combination with iNO):

- Sub-Cohort 2 (n=10) will be monitored with EIT before and after 15 minutes receiving 20ppm iNO in an OFF-ON fashion, both in the supine and in the prone position. A second EIT measurement off iNO will not be obtained to minimize the total dose of hypertonic saline solution. The subjects will be transported to the computed tomography (CT) room, and DECT will be performed first in the supine position. A second DECT will be obtained after 30 minutes in the prone position. No iNO will be given during DECT.

Methods to answer question 3 (To compare changes of regional lung perfusion due to iNO detected by EIT against the changes detected by gold standard DECT):

- 10 subjects in Sub-Cohort 1 will receive DECT in addition to EIT monitoring in the supine position. DECT will be obtained before the iNO delivery. Then, the iNO delivery will start, and after 15 minutes, DECT will be repeated.

Methods to answer question 4 (to define correlations between EIT-derived perfusion changes during an iNO challenge and clinical characteristics and outcomes. ):

- The investigators will explore the vascular response measured by EIT from all 70 subjects and categorize subjects accordingly. The investigators plan to apply EIT patterns as an image marker and use them in conjunction with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS severity.

Finally,

  • Blood MetHb levels will be continuously monitored before, during, and after each iNO administration of the day. At the end of each iNO administration, MetHb will continue to be monitored until values return to the level recorded before the current treatment and
  • The NO, nitrogen dioxide (NO2) will be continuously monitored by INOmax DSIR (Mallinckrodt) deliver system.
03

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Ventilation Perfusion Mismatch

Keywords

  • Acute respiratory distress syndrome
  • Ventilation/perfusion mismatch
  • Electrical impedance tomography
  • Inhaled nitric oxide
  • Dual-energy computed tomography
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult intubated and mechanically ventilated patients (≥ 18 years old) admitted to the intensive care unit (ICU)
  • ARDS diagnosis with mild to moderate severity by Berlin criteria1 (100 mmHg \< PaO2/FiO2 \<= 300 mmHg)
  • Presence of an arterial line for blood gas measurement and blood pressure monitoring and of a central line for hypertonic saline injection

Exclusion criteria

Exclusion criteria

  • Suspected pregnancy, pregnancy or less than six weeks postpartum
  • Younger than 18 years or older than 80 years
  • Patients with thorax perimeter not within the range of 37.5 - 134cm
  • Baseline methemoglobin ≥ 5%
  • level less than 7 g/dl
  • Subjects enrolled in another interventional research study
  • Presence of pneumothorax
  • Usage of any devices with the electric current generation, such as a pacemaker or internal cardiac defibrillator
  • Past medical history of severe lung disease
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Cytochrome b5 reductase deficiency
  • Sickle cell disease
  • Patients that are receiving inhaled pulmonary vasodilators at the time of the enrollment
  • Hemodynamic instability is defined as:

    • Persistent systolic blood pressure \<90 mmHg and/or >180 mmHg despite the use of vasopressor or vasodilators, or
    • Requiring an increment in inotropic vasopressors over the past two hours just before enrollment: more than 15 mcg/min for norepinephrine and dopamine, more than 10 mcg/min in epinephrine, and more than 50 mcg/ min for phenylephrine.
  • Increase in FiO2 > 20%, increase in PEEP > 5cmH2O over the past two hours just before enrollment
  • Hypernatremia (serum sodium > 150 mEq/L)
  • Patients cannot be enrolled for DECT if they have:

    • History of allergic reaction to intravenous contrast
    • Renal dysfunction on the day of the study (serum creatinine > 1.5 mg/dL)
  • Limited to sub-cohort 2: to prone positioning.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Electrical Impedance Tomography

    A total of 60 subjects (Sub-Cohort 1) will receive an inhaled nitric oxide (iNO) challenge (20 ppm) for 15 min. The investigators will measure ventilation and perfusion distributions using EIT before iNO ("OFF1"), after 15 min on iNO ("ON"), and after 15 min washout ("OFF2") to confirm baseline stability.

    Device: Nitric Oxide

  • Experimental
    Electrical Impedance Tomography and Dual-Energy Computed Tomography in the Supine and Prone position

    In a subset of 10 subjects (Sub-Cohort 2), EIT will be performed without and with iNO (OFF-ON) both in the supine and in the prone position. The OFF-ON fashion for EIT imaging is to minimize the subject's exposure to hypertonic saline solution. Sub-cohort 2 patient will be imaged also with DECT in the supine and after 30 minutes in the prone position. iNO will not be administered during DECT.

    Device: Nitric Oxide

  • Experimental
    Electrical Impedance Tomography with and without Inhaled Nitric Oxide in the Supine Position

    10 subjects (Sub-Cohort 3) from Sub-Cohort 1 will be monitored without iNO, with iNO, and without iNO (OFF-ON-OFF) in the supine position. Sub-Cohort 3 subjects will be imaged also with DECT. Imaging will be performed in the supine position without iNO and following iNO administration for 15 minutes (OFF-ON) .

    Device: Nitric Oxide

Interventions

  • DeviceNitric Oxide

    20ppm for 15 minutes delivered by INO max(Nitric Oxide) Company : INO therapeutics, Inc.

    Also known as: inhaled nitric oxide (iNO)

06

What researchers measure

Primary outcomes

  1. Change in regional lung perfusion after the delivery of inhaled nitric oxide

    The primary outcome is to detect changes in regional perfusion distribution with the administration of inhaled nitric oxide with electrical impedance tomography by measuring changes in impedance.

    Time frame: Day 1

Secondary outcomes

  1. Compare methods to detect change in regional lung perfusion after the delivery of inhaled nitric oxide

    The secondary outcome is to To compare electrical impedance tomography measurements against the gold standard dual-energy computed tomography (DECT)

    Time frame: Day 1

Other outcomes

  1. Age

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes. Age (years)

    Time frame: Day 1

  2. Gender

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1

  3. Height

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1

  4. Weight

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1

  5. Race

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1

  6. Ethnicity

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1

  7. Comorbidities

    Presence in the past medical history of conditions such as hypertension, diabetes,obesity, COPD, liver disease, and heart failure, among others. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1

  8. Hours Elapsed since intubation

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1

  9. Apache II score

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Within 24 hours of intensive care admission

  10. Intensive care unit survival at 28 days

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 28

  11. Hospital survival at 28 days

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 28

  12. Ventilation-free days

    This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: From day 1 to day 28

  13. PaO2

    The PaO2 will be measured with an arterial blood sample. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1, arterial blood gas samples will be taken at two time points: before and 1 hour after iNO. Subsequent days up to 28 days will be determined by the critical care staff

  14. PaCO2

    The PaCO2 will be measured with an arterial blood sample. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1, arterial blood gas samples will be taken at two time points: before and 1 hour after iNO. Subsequent days up to 28 days will be determined by the critical care staff

  15. Ph

    The Ph will be measured with an arterial blood sample. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1, arterial blood gas samples will be taken at two time points: before and 1 hour after iNO. Subsequent days up to 28 days will be determined by the critical care staff

  16. Methemoglobin (MetHb)

    The MetHb will be measured with an arterial blood sample. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1, arterial blood gas samples will be taken at two time points: before and 1 hour after iNO. Subsequent days up to 28 days will be determined by the critical care staff

  17. HCO3 (bicarbonate)

    The HCO3 will be measured with an arterial blood sample. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: Day 1, arterial blood gas samples will be taken at two time points: before and 1 hour after iNO. Subsequent days up to 28 days will be determined by the critical care staff

  18. Tidal Volume

    Ventilator Parameter. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: From day 1 to day 28

  19. Plateau, peak and positive end-expiratory pressures

    Ventilator Parameters are measured during tidal ventilation, inspiratory and expiratory holds. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: From day 1 to day 28

  20. Respiratory rate

    Ventilator Parameters are measured during tidal ventilation, inspiratory and expiratory holds. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: From day 1 to day 28

  21. Flow

    Ventilator Parameters are measured during tidal ventilation, inspiratory and expiratory holds. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: From day 1 to day 28

  22. Vasopressors requirements (dopamine, dobutamine, epinephrine, levosimendan, milrinone, vasopressin, norepinephrine)

    We will calculate the Vasoactive-inotropic score (VIS). The VIS compares different vasoactive-inotropic drugs and doses among the patients. VIS = dopamine dose (mg/kg/min)+ dobutamine \[mg/kg/min) +100 x epinephrine dose (mg/ kg/min) +50 x levosimendan dose \[mg/kg/min) + 10 x milrinone dose \[mg/kg/min)+ 10,000 x vasopressin \[units/kg/min) + 100x norepinephrine dose \[mg/kg/min) using the maximum dosing rates of vasoactive and inotropic medications. Ref: Koponen et al. British Journal of Anaesthesia, 122 (4): 428e436 (2019). This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: From day 1 to day 28

  23. Arterial blood pressure, central venous pressure, pulmonary artery pressure

    Hemodynamic parameters. The pulmonary artery pressure will be measured if the subject have a pulmonary artery pressure placed by the ICU staff with clinical purposes. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: From day 1 to day 28

  24. Life sustaining therapies

    Other life-sustaining therapies than mechanical ventilation and vasopressors administration: Antibiotics, Renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), chemotherapy, and artificial nutrition. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: From day 1 to day 28

  25. CRP, MCP-1, TNF-alpha, IL-6, IL-8, IL-10, Ang-2, VEGF

    Blood samples will be collected and Systemic markers of inflammation and plasma cytokines: CRP, MCP-1, TNF-alpha, IL-6, IL-8, IL-10, Ang-2, VEGF will be measured. This exploratory outcome plans to utilize electrical impedance tomography as an image marker and combine them with other markers (demographical, radiological, clinical, biochemical, and inflammatory) to identify ARDS sub-phenotypes.

    Time frame: From day 1 to day 28

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669. PubMed 22797452 ↗
  • Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, Herridge M, Randolph AG, Calfee CS. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019 Mar 14;5(1):18. doi: 10.1038/s41572-019-0069-0. PubMed 30872586 ↗
  • Cressoni M, Caironi P, Polli F, Carlesso E, Chiumello D, Cadringher P, Quintel M, Ranieri VM, Bugedo G, Gattinoni L. Anatomical and functional intrapulmonary shunt in acute respiratory distress syndrome. Crit Care Med. 2008 Mar;36(3):669-75. doi: 10.1097/01.CCM.0000300276.12074.E1. PubMed 18091555 ↗
  • Zapol WM, Kobayashi K, Snider MT, Greene R, Laver MB. Vascular obstruction causes pulmonary hypertension in severe acute respiratory failure. Chest. 1977 Feb;71(2 suppl):306-7. doi: 10.1378/chest.71.2_supplement.306. No abstract available. PubMed 836381 ↗
  • Greene R, Zapol WM, Snider MT, Reid L, Snow R, O'Connell RS, Novelline RA. Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis. 1981 Nov;124(5):593-601. doi: 10.1164/arrd.1981.124.5.593. No abstract available. PubMed 7305115 ↗
  • Tomashefski JF Jr, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol. 1983 Jul;112(1):112-26. PubMed 6859225 ↗
  • Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993 Feb 11;328(6):399-405. doi: 10.1056/NEJM199302113280605. PubMed 8357359 ↗
  • Johnson TR. Dual-energy CT: general principles. AJR Am J Roentgenol. 2012 Nov;199(5 Suppl):S3-8. doi: 10.2214/AJR.12.9116. PubMed 23097165 ↗
  • Borges JB, Suarez-Sipmann F, Bohm SH, Tusman G, Melo A, Maripuu E, Sandstrom M, Park M, Costa EL, Hedenstierna G, Amato M. Regional lung perfusion estimated by electrical impedance tomography in a piglet model of lung collapse. J Appl Physiol (1985). 2012 Jan;112(1):225-36. doi: 10.1152/japplphysiol.01090.2010. Epub 2011 Sep 29. PubMed 21960654 ↗
  • Safaee Fakhr B, Araujo Morais CC, De Santis Santiago RR, Di Fenza R, Gibson LE, Restrepo PA, Chang MG, Bittner EA, Pinciroli R, Fintelmann FJ, Kacmarek RM, Berra L. Bedside monitoring of lung perfusion by electrical impedance tomography in the time of COVID-19. Br J Anaesth. 2020 Nov;125(5):e434-e436. doi: 10.1016/j.bja.2020.08.001. Epub 2020 Aug 7. No abstract available. PubMed 32859359 ↗
  • Morais CCA, Safaee Fakhr B, De Santis Santiago RR, Di Fenza R, Marutani E, Gianni S, Pinciroli R, Kacmarek RM, Berra L. Bedside Electrical Impedance Tomography Unveils Respiratory "Chimera" in COVID-19. Am J Respir Crit Care Med. 2021 Jan 1;203(1):120-121. doi: 10.1164/rccm.202005-1801IM. No abstract available. PubMed 33196303 ↗
  • De Santis Santiago R, Teggia Droghi M, Fumagalli J, Marrazzo F, Florio G, Grassi LG, Gomes S, Morais CCA, Ramos OPS, Bottiroli M, Pinciroli R, Imber DA, Bagchi A, Shelton K, Sonny A, Bittner EA, Amato MBP, Kacmarek RM, Berra L; Lung Rescue Team Investigators. High Pleural Pressure Prevents Alveolar Overdistension and Hemodynamic Collapse in Acute Respiratory Distress Syndrome with Class III Obesity. A Clinical Trial. Am J Respir Crit Care Med. 2021 Mar 1;203(5):575-584. doi: 10.1164/rccm.201909-1687OC. PubMed 32876469 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 29 months is above that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2023
First posted
Apr 6, 2023
StartActual
Jul 10, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 exclusion criteria edited, 8 added, 2 removed
What changed in the criteria
Exclusion criteria
  • AddedPatients with thorax perimeter not within the range of 37.5 - 134cm
  • AddedHemoglobin level less than 7 g/dl
  • EditedUsage of any devices with the electric current generation, such as a pacemaker or internal cardiac defibrillator
  • RemovedPreexisting chronic lung disease or pulmonary hypertension
  • EditedPast medical history of lung malignancy or pneumonectomy, orsevere lung transplantdisease
  • RemovedLeft ventricle ejection fraction <20%
  • AddedGlucose-6-phosphate dehydrogenase (G6PD) deficiency
  • AddedCytochrome b5 reductase deficiency
  • AddedSickle cell disease
  • AddedPatients that are receiving inhaled pulmonary vasodilators at the time of the enrollment
  • AddedIncrease in FiO2 > 20%, increase in PEEP > 5cmH2O over the past two hours just before enrollment
  • AddedLimited to sub-cohort 2: contraindications to prone positioning.
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Eligibility 2 exclusion criteria edited, 8 added, 2 removed
    What changed in the criteria
    Exclusion criteria
    • AddedPatients with thorax perimeter not within the range of 37.5 - 134cm
    • AddedHemoglobin level less than 7 g/dl
    • EditedUsage of any devices with the electric current generation, such as a pacemaker or internal cardiac defibrillator
    • RemovedPreexisting chronic lung disease or pulmonary hypertension
    • EditedPast medical history of lung malignancy or pneumonectomy, orsevere lung transplantdisease
    • RemovedLeft ventricle ejection fraction <20%
    • AddedGlucose-6-phosphate dehydrogenase (G6PD) deficiency
    • AddedCytochrome b5 reductase deficiency
    • AddedSickle cell disease
    • AddedPatients that are receiving inhaled pulmonary vasodilators at the time of the enrollment
    • AddedIncrease in FiO2 > 20%, increase in PEEP > 5cmH2O over the past two hours just before enrollment
    • AddedLimited to sub-cohort 2: contraindications to prone positioning.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05801224
Responsible party
Maurizio F. Cereda, MD (MD, Member of the Faculty of Anaesthesia, Massachusetts General Hospital) — Principal investigator
First posted
Apr 6, 2023
Start date
Jul 10, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Maurizio F Cereda, MD
Contact
mcereda@mgh.harvard.edu
6177263030
Roberta Ribeiro De Santis Santiago, MD, PhD
Contact
rrsantiago@mgh.harvard.edu
6176437733
Maurizio Cereda, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion